Licensing · Global (LMICs) · Announced 31 Jul 2026
IMPACT Therapeutics → Pharmanovia
IMPACT Therapeutics granted Pharmanovia exclusive rights to its PARP inhibitor senaparib in 66 countries across Europe, MENA, Australia and New Zealand, for up to EUR 423.5 million plus royalties.
Parties: IMPACT Therapeutics (China) → Pharmanovia (United Kingdom)
- Deal type
- Licensing
- Value
- See terms
- Territory
- 66 countries: EU-27, UK, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand and MENA countries
- Therapeutic area
- Oncology
- Asset
- Senaparib
- Announced
- 31 Jul 2026
Our analysis
Why this matters
On 31 July 2026, Shanghai-based IMPACT Therapeutics (HKEX: 07630) signed an exclusive licence giving Pharmanovia rights to manufacture, develop and commercialise senaparib, its in-house PARP1/2 inhibitor, in 66 countries. The territory covers the EU, the UK, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand and MENA countries. Total consideration is up to EUR 423.5 million, made up of an upfront payment, near-term regulatory milestones and sales milestones, plus tiered royalties up to the mid-twenties percent. The upfront amount was not disclosed.
Senaparib is approved in China (NMPA, January 2025) as first-line maintenance monotherapy for advanced epithelial high-grade ovarian, fallopian tube and primary peritoneal cancer, and has been reimbursed there since January 2026. The EMA accepted its marketing application in August 2025, with a decision expected in the second half of 2026. IMPACT calls the deal its first step outside China.
The full analysis is free to read with a work email on this page.
Source: PR Newswire via BioSpace